Skip to main content
Be The Investor
BTI Market Newsearnings
Back to News

BioMarin Tops $1 Billion in Revenue but Cuts 2026 Guidance

BioMarin Tops $1 Billion in Revenue but Cuts 2026 Guidance

BioMarin's quarterly revenue rose 32% and exceeded $1 billion for the first time, but deal costs and Voxzogo timing drove a sharp reduction in its 2026 earnings outlook.

BioMarin crossed $1 billion of quarterly revenue for the first time, but the milestone came with a much weaker full-year earnings outlook. Third-quarter revenue rose 32% from a year earlier to $1.025 billion, driven by acquired metabolic products and continued growth in the skeletal-conditions portfolio.

Metabolic revenue increased 44%, while skeletal-conditions revenue rose 12%. GALAFOLD contributed $152 million and POMBILITI plus OPFOLDA generated $49 million. The number of patients on those therapies increased 13% and 69%, respectively.

VOXZOGO revenue grew 12%, with patient volume up 17%. More than 75% of product revenue came from outside the United States. Management said a large international order expected in the third quarter moved into the fourth quarter, creating a timing issue rather than confirmed lost demand. Even so, the company reduced full-year VOXZOGO guidance to $975 million to $1.025 billion from $1.0 billion to $1.05 billion.

Loading market context

BioMarin also narrowed and lowered total revenue guidance. The new range is $3.8 billion to $3.9 billion, compared with $3.875 billion to $3.925 billion previously. Metabolic-product guidance fell to $2.675 billion to $2.75 billion from $2.725 billion to $2.775 billion.

The larger change was in profitability. BioMarin reported a GAAP net loss of $123 million, compared with a $31 million loss a year earlier. Acquisition-related amortization, interest, inventory step-up, integration and restructuring costs contributed to the decline, as did in-process research and development expense. Non-GAAP net income was $45 million, up from $22 million, showing why investors need to keep the reported and adjusted views separate.

Full-year non-GAAP EPS guidance dropped to $2.80 to $3.10 from $4.90 to $5.10. The company attributed much of the reduction to a $320 million pre-tax expense from the Alesta transaction and an $83 million expense tied to the BMN 450 license, with estimated effects of $1.55 and $0.32 a share, respectively. These are identifiable deal costs, but they are still economic uses of capital.

Two regulatory dates now provide concrete milestones. The U.S. Food and Drug Administration has set May 30, 2027 as the target action date for VOXZOGO in hypochondroplasia and February 28, 2027 for full approval in achondroplasia.

The quarter showed real commercial momentum, especially in the acquired metabolic franchise. The investment debate is whether that growth can outweigh near-term deal costs and restore confidence in earnings. Fourth-quarter VOXZOGO ordering and the integration of the newer products will be the clearest tests.

Image references: · Shop Apotheke actual German BioMarin Voxzogo 0.56 mg package reference (Reference copyright retained by its owner; factual visual research, no CC grant claimed.)